相似文献
1
Predicting progression in patients with Parkinson's disease.
Lancet Neurol. 2017 Nov;16(11):860-862. doi: 10.1016/S1474-4422(17)30331-9. Epub 2017 Sep 25.
2
Can neuroimaging predict dementia in Parkinson's disease?
Brain. 2018 Sep 1;141(9):2545-2560. doi: 10.1093/brain/awy211.
3
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Brain. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118.
4
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9.
5
Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
Brain. 2017 Aug 1;140(8):2183-2192. doi: 10.1093/brain/awx146.
6
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.
Clin Transl Sci. 2019 May;12(3):240-246. doi: 10.1111/cts.12619. Epub 2019 Mar 18.
7
Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.
PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016.
8
Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures.
Parkinsonism Relat Disord. 2021 Apr;85:44-51. doi: 10.1016/j.parkreldis.2021.02.026. Epub 2021 Mar 7.
9
Parkinson's disease tremors and serotonin.
Brain. 2018 Mar 1;141(3):624-626. doi: 10.1093/brain/awx361.
10
Advances in imaging in Parkinson's disease.
Lancet Neurol. 2011 Nov;10(11):987-1001. doi: 10.1016/S1474-4422(11)70214-9.
引用本文的文献
1
Quality of life and living with Parkinson's disease: a qualitative exploration within an Irish context.
BMC Neurol. 2024 Aug 8;24(1):275. doi: 10.1186/s12883-024-03769-y.
2
The emerging postural instability phenotype in idiopathic Parkinson disease.
NPJ Parkinsons Dis. 2022 Mar 18;8(1):28. doi: 10.1038/s41531-022-00287-x.
3
Parkinson's progression prediction using machine learning and serum cytokines.
NPJ Parkinsons Dis. 2019 Jul 25;5:14. doi: 10.1038/s41531-019-0086-4. eCollection 2019.
4
SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
Mov Disord. 2019 Sep;34(9):1333-1344. doi: 10.1002/mds.27770. Epub 2019 Jun 24.
本文引用的文献
1
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25.
2
Imaging genetics approach to Parkinson's disease and its correlation with clinical score.
Sci Rep. 2017 Apr 21;7:46700. doi: 10.1038/srep46700.
3
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.
4
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.
5
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
Mov Disord. 2016 Jan;31(1):79-85. doi: 10.1002/mds.26374. Epub 2015 Aug 13.
6
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.
Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.
7
The Parkinson Progression Marker Initiative (PPMI).
Prog Neurobiol. 2011 Dec;95(4):629-35. doi: 10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14.
8
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690.
9
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.
Zotero 插件